Renal Pelvic Denervation Pilot Trial

The RPD Pilot trial will evaluate the safety and effectiveness of Verve Medical's RPDTM renal denervation system for hypertensive patients with uncontrolled blood pressure despite use of two medications at a therapeutic dose. The novelty of the RPDTM system relates to its placement via natural orifice into the renal pelvis (bilaterally) for delivery of radiofrequency energy to ablate the nerves that pass through the outer wall of the renal pelvis, a technique referred to as renal pelvic denervation (RPD).

NCT Number	NCT07005050
Lead Sponsor	Verve Medical, Inc Collaborators: RQM+, Dabl Ltd, Medical Labs Memphis - MLM
Conditions	Uncontrolled Hypertension
Enrollment	60 participants
Start Date	2025-12-30
Primary Completion	2026-10-30 (estimated)
Study Completion	2029-03-02 (estimated)
Updated on ClinicalTrials.gov	2026-01-08